General Information of Drug Combination (ID: DCP1IMR)

Drug Combination Name
Linagliptin Sumatriptan
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Linagliptin   DMWFJTR Sumatriptan   DMVYXR8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 4.96
Bliss Independence Score: 4.96
Loewe Additivity Score: 19.8
LHighest Single Agent (HSA) Score: 19.81

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Linagliptin
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [2]
Type 2 diabetes 5A11 Approved [3]
Type-2 diabetes 5A11 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Linagliptin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [8]
HUMAN dipeptidyl peptidase 4 (DPP-4) TTF928K DPP4_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Linagliptin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Indication(s) of Sumatriptan
Disease Entry ICD 11 Status REF
Cluster headache 8A81.0 Approved [6]
Migraine 8A80 Approved [7]
Migraine disorder N.A. Approved [6]
Sumatriptan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [11]
------------------------------------------------------------------------------------
Sumatriptan Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [13]
------------------------------------------------------------------------------------
Sumatriptan Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Decreases Expression [14]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Decreases Expression [15]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3) OTA6HYBA GBB3_HUMAN Increases Response [16]
5-hydroxytryptamine receptor 1F (HTR1F) OTALAXPA 5HT1F_HUMAN Increases ADR [17]
Calcitonin gene-related peptide 1 (CALCA) OTQSXM9Z CALCA_HUMAN Increases ADR [17]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Linagliptin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318).
5 ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
6 Sumatriptan FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 54).
8 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
9 DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
10 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
11 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
12 HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J Pharm Sci. 2001 Oct;90(10):1608-19. Comparative Study
13 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
14 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
15 The effects of oral sumatriptan, a 5-HT1 receptor agonist, on circulating ACTH and cortisol concentrations in man. Br J Clin Pharmacol. 1995 Apr;39(4):389-95. doi: 10.1111/j.1365-2125.1995.tb04467.x.
16 G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007 Oct;82(4):396-401. doi: 10.1038/sj.clpt.6100159. Epub 2007 Mar 14.
17 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.